Inside Selling: Ravindra Kumar Unloaded 1,203 Shares of Acceleron Pharma Inc. (XLRN); 2 Bullish Analysts Covering Sharps Compliance Corp. (SMED)

Sharps Compliance Corp. (NASDAQ:SMED) Logo

Among 2 analysts covering Sharps Compliance (NASDAQ:SMED), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Sharps Compliance had 6 analyst reports since September 23, 2015 according to SRatingsIntel. On Friday, August 12 the stock rating was downgraded by First Analysis to “Equal-Weight”. Stifel Nicolaus maintained the shares of SMED in report on Wednesday, September 23 with “Buy” rating. Stifel Nicolaus maintained the stock with “Buy” rating in Friday, August 11 report. First Analysis upgraded it to “Buy” rating and $800 target in Monday, August 14 report. The company was maintained on Thursday, October 26 by Stifel Nicolaus. On Wednesday, July 19 the stock rating was maintained by Stifel Nicolaus with “Buy”. See Sharps Compliance Corp. (NASDAQ:SMED) latest ratings:

26/10/2017 Broker: Stifel Nicolaus Rating: Buy Old Target: $7 New Target: $6 Maintain

Investors sentiment decreased to 1 in 2017 Q4. Its down 0.57, from 1.57 in 2017Q3. It dropped, as 4 investors sold Sharps Compliance Corp. shares while 9 reduced holdings. 5 funds opened positions while 8 raised stakes. 3.87 million shares or 4.85% less from 4.06 million shares in 2017Q3 were reported. Bancshares Of America De accumulated 10,000 shares. Heartland Advisors Inc reported 189,144 shares or 0.05% of all its holdings. Morgan Stanley stated it has 0% in Sharps Compliance Corp. (NASDAQ:SMED). Lapides Asset Mgmt Lc reported 0.11% in Sharps Compliance Corp. (NASDAQ:SMED). Cadence Cap Mngmt Lc has invested 0.06% in Sharps Compliance Corp. (NASDAQ:SMED). Barclays Public Ltd Company holds 0% or 1 shares in its portfolio. Deutsche Bank & Trust Ag invested in 0% or 28,484 shares. Tower Rech (Trc) stated it has 863 shares. Vanguard Group Inc invested 0% in Sharps Compliance Corp. (NASDAQ:SMED). Anderson Hoagland Co stated it has 0.05% in Sharps Compliance Corp. (NASDAQ:SMED). Bankshares Of Mellon holds 13,726 shares. Dimensional Fund Advisors Limited Partnership owns 14,013 shares. Blackrock invested in 103,302 shares or 0% of the stock. Ranger Inv Management Lp has 0.11% invested in Sharps Compliance Corp. (NASDAQ:SMED) for 379,765 shares. Thompson Davis And Com holds 0.07% or 7,440 shares in its portfolio.

The stock increased 0.68% or $0.03 during the last trading session, reaching $4.45. About 2,617 shares traded. Sharps Compliance Corp. (NASDAQ:SMED) has declined 7.71% since April 5, 2017 and is downtrending. It has underperformed by 19.26% the S&P500.

Sharps Compliance Corp. provides medical, pharmaceutical, and hazardous waste management services in the United States. The company has market cap of $71.57 million. It offers Sharps Recovery System for the containment, transportation, treatment, and tracking of medical waste and used healthcare materials generated outside the hospital and health care facility settings; TakeAway Medication Recovery System, a solution that facilitates the proper disposal of unused medications; MedSafe, a solution for the safe collection, transportation, and proper disposal of unwanted and expired prescription medications; and ComplianceTRAC, a Web compliance and training program. It has a 556.25 P/E ratio. The firm also provides Route-Based Pickup Service, a waste management service, which offers medical and hazardous waste pick-up services; TakeAway Recycle System, a solution for the collection and recycling of single-use medical devices from surgical centers and other healthcare facilities; and Universal Waste Shipback Systems, a solution for the collection, transportation, and recycling of light bulbs, batteries, and other mercury containing devices.

Since December 15, 2017, it had 0 insider buys, and 8 sales for $7.28 million activity. $183,806 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) was sold by Quisel John D on Tuesday, January 2. $96,134 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) was sold by Rovaldi Christopher. George Jean sold $3.76 million worth of stock or 105,122 shares. 37,500 shares were sold by POPS RICHARD F, worth $1.55M. 19,000 shares valued at $814,848 were sold by MCLAUGHLIN KEVIN F on Tuesday, January 2. $197,868 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) was sold by Sherman Matthew L. Shares for $182,363 were sold by Kumar Ravindra.

Ravindra Kumar is the SVP & Chief Scientific Officer of Acceleron Pharma Inc. He lately unloaded 1,203 shares in the ‘s company with the sale value amounting to nearly $46,205 U.S. Dollars. This is based on the revealed price of $38.4 for each share. Presently, he holds 95,935 shares or 0.21% of Acceleron Pharma Inc’s market capitalization (total value of the shares outstanding).

Investors sentiment decreased to 1.09 in Q4 2017. Its down 0.72, from 1.81 in 2017Q3. It fall, as 24 investors sold Acceleron Pharma Inc. shares while 32 reduced holdings. 14 funds opened positions while 47 raised stakes. 38.14 million shares or 1.07% more from 37.73 million shares in 2017Q3 were reported. Cornerstone Cap Ltd Liability Corp invested 0.01% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN). Loring Wolcott Coolidge Fiduciary Advsr Llp Ma invested 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Meeder Asset Incorporated owns 231 shares for 0% of their portfolio. Qvt Lp holds 0.89% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN) for 373,481 shares. Fmr Ltd Limited Liability Company holds 5.11 million shares or 0.03% of its portfolio. United Kingdom-based Barclays Pcl has invested 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Rhumbline Advisers invested in 0% or 37,484 shares. Great Point Prtn Ltd Llc reported 173,124 shares. The Illinois-based Citadel Advisors Llc has invested 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Royal National Bank Of Canada holds 0% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN) for 316 shares. Hamilton Lane Advsr Ltd Limited Liability Company accumulated 69,503 shares or 1.52% of the stock. Eventide Asset Mgmt Lc owns 653,900 shares for 1.45% of their portfolio. Alps Incorporated invested in 50,125 shares or 0.01% of the stock. Franklin Resource holds 435,577 shares. Alliancebernstein Lp holds 0% or 69,000 shares.

Analysts await Acceleron Pharma Inc. (NASDAQ:XLRN) to report earnings on May, 14. They expect $-0.64 earnings per share, up 3.03% or $0.02 from last year’s $-0.66 per share. After $-0.62 actual earnings per share reported by Acceleron Pharma Inc. for the previous quarter, Wall Street now forecasts 3.23% negative EPS growth.

The stock increased 0.55% or $0.21 during the last trading session, reaching $38.35. About 813,806 shares traded or 162.37% up from the average. Acceleron Pharma Inc. (NASDAQ:XLRN) has risen 45.87% since April 5, 2017 and is uptrending. It has outperformed by 34.32% the S&P500.

Among 16 analysts covering Acceleron Pharma (NASDAQ:XLRN), 12 have Buy rating, 1 Sell and 3 Hold. Therefore 75% are positive. Acceleron Pharma has $63 highest and $20 lowest target. $45.71’s average target is 19.19% above currents $38.35 stock price. Acceleron Pharma had 40 analyst reports since August 13, 2015 according to SRatingsIntel. The company was maintained on Friday, June 23 by Oppenheimer. As per Tuesday, November 14, the company rating was maintained by Credit Suisse. FBR Capital maintained the stock with “Outperform” rating in Monday, January 18 report. The rating was downgraded by Oppenheimer to “Market Perform” on Tuesday, June 13. Janney Capital initiated the stock with “Neutral” rating in Thursday, December 17 report. Barclays Capital maintained Acceleron Pharma Inc. (NASDAQ:XLRN) on Wednesday, February 28 with “Overweight” rating. As per Thursday, March 2, the company rating was upgraded by Citigroup. On Tuesday, December 13 the stock rating was initiated by Oppenheimer with “Outperform”. RBC Capital Markets maintained Acceleron Pharma Inc. (NASDAQ:XLRN) on Thursday, November 2 with “Hold” rating. The company was maintained on Tuesday, August 1 by Oppenheimer.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases. The company has market cap of $1.74 billion. The Company’s therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases. It currently has negative earnings. The companyÂ’s therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy.

Sharps Compliance Corp. (NASDAQ:SMED) Institutional Positions Chart